Seminars in Cancer Biology

Papers
(The H4-Index of Seminars in Cancer Biology is 78. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
Editorial Board436
Editorial Board407
Deregulated transcription factors in the emerging cancer hallmarks312
Targeting Hippo signaling pathway by phytochemicals in cancer therapy238
Biology of cancer; from cellular and molecular mechanisms to developmental processes and adaptation234
The molecular chaperone TRAP1 in cancer: From the basics of biology to pharmacological targeting214
Critical DNA damaging pathways in tumorigenesis212
Multifaceted role of chemokines in solid tumors: From biology to therapy207
Advances in biology and novel treatments of SCLC204
Carbonic anhydrase IX: A tumor acidification switch in heterogeneity and chemokine regulation202
Unveiling the role of PIK3R1 in cancer: A comprehensive review of regulatory signaling and therapeutic implications187
Small secretory proteins of immune cells can modulate gynecological cancers185
Emerging applications of bacteria as antitumor agents183
Updated review on green tea polyphenol epigallocatechin-3-gallate as a cancer epigenetic regulator181
Editorial Board178
Special issue: Deregulated transcription factors in the cancer therapeutic challenges: An update on cancer stemness features174
Editorial Board172
Gut microbes in gastrointestinal cancers171
PIWI-interacting RNAs in human cancer169
Excess body weight and postmenopausal breast cancer: Emerging molecular mechanisms and perspectives159
Erratum to “RNA regulatory mechanisms controlling TGF-β signaling and EMT in cancer” [Semin. Cancer Biol. 102–103 (2024) 4–16]159
Innovative trial design in precision oncology156
Immune cellular components and signaling pathways in the tumor microenvironment150
Multifaceted functions of chronic inflammation in regulating tumor dormancy and relapse142
Thinking small to win big? A critical review on the potential application of extracellular vesicles for biomarker discovery and new therapeutic approaches in pancreatic cancer138
Anticancer properties of chimeric HDAC and kinase inhibitors136
Association of Chlamydia and Mycoplasma infections with susceptibility to ovarian cancer: A systematic review and meta-analysis136
Origins and molecular effects of hypoxia in cancer135
Targeting micro-environmental pathways by PROTACs as a therapeutic strategy132
Microbiome dysbiosis and epigenetic modulations in lung cancer: From pathogenesis to therapy130
Enhancing head and neck tumor management with artificial intelligence: Integration and perspectives128
Extracellular vesicles associated microRNAs: Their biology and clinical significance as biomarkers in gastrointestinal cancers127
Genome chaos: Creating new genomic information essential for cancer macroevolution123
The IL-1 family in tumorigenesis and antitumor immunity120
Targeting monocarboxylate transporters (MCTs) in cancer: How close are we to the clinics?118
Molecular targets of tyrosine kinase inhibitors in thyroid cancer118
New biological and immunological approaches to cancer therapy: Basic and clinical aspects116
Reprogramming of glycolysis by chemical carcinogens during tumor development115
Cellular stress responses and metabolic reprogramming in cancer progression and dormancy109
Multi-omic markers of intraductal papillary mucinous neoplasms progression into pancreatic cancer109
Therapy-induced modulation of extracellular vesicles in hepatocellular carcinoma108
Vibrational spectroscopy for decoding cancer microbiota interactions: Current evidence and future perspective107
Modulation of the tumor microenvironment by natural agents: implications for cancer prevention and therapy106
Extracellular vesicles in glioblastoma: Biomarkers and therapeutic tools106
Unravelling the complexities of resistance mechanism in pancreatic cancer: Insights from in vitro and ex-vivo model systems106
Curcumin and colorectal cancer: An update and current perspective on this natural medicine105
The intricacies of NRF2 regulation in cancer105
Cancer cell heterogeneity & plasticity in glioblastoma and brain tumors104
Metabolic landscape and rewiring in normal hematopoiesis, leukemia and aging102
Editorial Board102
Atrial fibrillation in cancer patients: Epidemiology, identification and management102
Anticancer natural products targeting immune checkpoint protein network102
Regulation of epithelial-mesenchymal transition by tumor microenvironmental signals and its implication in cancer therapeutics101
Targeting the “undruggable”: RNA-binding proteins in the spotlight in cancer therapy101
The role of deiodinases on metabolic alteration in cancer101
Regulation of the aryl hydrocarbon receptor in cancer and cancer stem cells of gynecological malignancies: An update on signaling pathways99
Role of LDH in tumor glycolysis: Regulation of LDHA by small molecules for cancer therapeutics97
How far have we explored fungi to fight cancer?97
Insight into the role of multiple signaling pathways in regulating cancer stem cells of gynecologic cancers97
Advancement of cancer immunotherapy using nanoparticles-based nanomedicine93
Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer92
Editorial Board91
Cytotoxic activity of l-lysine alpha-oxidase against leukemia cells91
Editorial Board91
The role of RNA processing and regulation in metastatic dormancy91
Leveraging epigenetic alterations in pancreatic ductal adenocarcinoma for clinical applications90
The foundational framework of tumors: Gametogenesis, p53, and cancer89
Transcription networks rewire gene repertoire to coordinate cellular reprograming in prostate cancer89
Metabolic reprogramming of tumor microenviroment by engineered bacteria87
Role of ubiquitination-driven metabolisms in oncogenesis and cancer therapy86
Mechanisms and applications of apolipoproteins and apolipoprotein mimetic peptides: Common pathways in cardiovascular disease and cancer85
BubR1 and SIRT2: Insights into aneuploidy, aging, and cancer84
Plant lectins and their usage in preparing targeted nanovaccines for cancer immunotherapy83
Drivers of centrosome abnormalities: Senescence progression and tumor immune escape81
Emerging perspectives on growth factor metabolic relationships in the ovarian cancer ascites environment80
Functionalized-DNA nanostructures as potential targeted drug delivery systems for cancer therapy79
Chaperonins in cancer: Expression, function, and migration in extracellular vesicles79
Advancements in small cell lung cancer78
Benefits and limitations of nanomedicine treatment of brain cancers and age-dependent neurodegenerative disorders78
Emerging roles of long noncoding RNAs in chemoresistance of pancreatic cancer78
0.17865800857544